Clinical trials: OHT - Ocular Hypertension
Glaucoma, Ocular Hypertension
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic…
- Trial name
- NCT02105272
- Testing
- OPC-1085EL ophthalmic solution, Latanoprost ophthalmic solution
- Where
- Japan
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Glaucoma
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.
This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of…
- Trial name
- T1030 (NCT01155219)
- Testing
- Geltim LP 1 mg/g, Xalatan
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Laboratoires Thea
Primary Open Angle Glaucoma
Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG
The purpose of this study is to evaluate the ocular hypotensive effect of the Hydrus Aqueous Implant (Standard and Low-Profile), as determined by the change in IOP from baseline (preoperative) and change in the number of glaucoma…
- Trial name
- POAG (NCT03065036)
- Testing
- prestudy topical glaucoma medications
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 120 people
- Sponsor
- Ivantis, Inc.
Open-angle Glaucoma
Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma
A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
- Trial name
- NCT03604328
- Testing
- PA5108
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma, Open-Angle, Ocular Hypertension
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.
- Trial name
- NCT00150267
- Testing
- Xalacom
- Where
- 74 sites in Australia, Belgium and 10 more
- Volunteers
- 976 people
- Sponsor
- Pfizer
Primary Open Angle Glaucoma, Pigmentary Glaucoma
IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty
Selective laser trabeculoplasty (SLT) is an increasingly popular treatment modality in early-to-moderate glaucoma patients. SLT has been suggested to reduce IOP more consistently during the nocturnal period than during the…
- Conditions
- Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT01767753
- Testing
- Sensimed Triggerfish
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Sensimed AG
Ocular Hypertension, Glaucoma
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
- Trial name
- NCT00800267
- Testing
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Where
- 53 sites in United States
- Volunteers
- 418 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-angle Glaucoma, Ocular Hypertension
Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00288951
- Testing
- Travoprost 0.004% with and without BAK
- Volunteers
- 690 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00670033
- Testing
- Travoprost ophthalmic solution (new formulation), Travoprost ophthalmic solution, 0.004%, Vehicle
- Volunteers
- 158 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily…
- Trial name
- NCT01068964
- Testing
- 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution, 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
- Trial name
- NCT01298700
- Testing
- bimatoprost 0.01% ophthalmic solution, bimatoprost 0.03% ophthalmic solution
- Where
- 50 sites in Belgium, Czechia and 8 more
- Volunteers
- 806 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks.
- Trial name
- NCT00061516
- Testing
- BETAXON (levobetaxolol HCl), AZOPT (brinzolamide)
- Volunteers
- 78 people
- Sponsor
- Alcon Research
Glaucoma, Open Angle, Ocular Hypertension
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure…
- Trial name
- NCT00140049
- Testing
- Xalacom, Cosopt
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)
A prospective, multicenter, open-label, safety and preliminary efficacy study of the surgical implantation of OPKO's glaucoma drainage device (AquashuntTM) in patients with refractory chronic forms of open angle glaucoma (OAG).
- Trial name
- NCT00834223
- Testing
- Aquashunt
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- OPKO Health, Inc.
Glaucoma, Ocular Hypertension
Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension.
- Trial name
- NCT07641296
- Testing
- BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug)
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Overactive Bladder
Specified Drug Use-results Survey of Betanis Tablets
To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.
- Trial name
- NCT01898624
- Testing
- mirabegron
- Where
- 7 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Astellas Pharma Inc
Diabetic Retinopathy, Diabetic Macular Edema
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Age-Related Macular Degeneration, Age-related Maculopathy
- Trial name
- OPHTAI-EVAL (NCT05752045)
- Testing
- Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device
- Where
- 12 sites in France
- Volunteers
- 1,389 people
- Sponsor
- Evolucare Technologies
Glaucoma, Ocular Hypertension
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
- Trial name
- NCT00767494
- Testing
- Travoprost/Brinzolamide fixed combination, Azopt, Travatan
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Alcon Research
Glaucoma
A Study to Evaluate the Clinical Performance of VeriSee GLC for Screening of Glaucoma Suspect Using Color Fundus Images
The goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants.
- Trial name
- NCT07550712
- Where
- Taiwan
- Volunteers
- 773 people
- Sponsor
- Acer Medical Inc.